Advances in the study of expression and regulation of P-glycoprotein.
- Author:
Cheng-Jun SHI
1
;
Li-Wu FU
Author Information
1. State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, Guangzhou 510060, China.
- Publication Type:Journal Article
- MeSH:
ATP-Binding Cassette, Sub-Family B, Member 1;
genetics;
metabolism;
Acetylation;
DNA Methylation;
Drug Resistance, Multiple;
Drug Resistance, Neoplasm;
Gene Expression Regulation, Neoplastic;
Genes, MDR;
Glycosylation;
Humans;
Neoplasms;
metabolism;
pathology;
Phosphorylation;
Polymorphism, Genetic;
Transcription Factors;
genetics;
metabolism
- From:
Acta Pharmaceutica Sinica
2007;42(9):911-916
- CountryChina
- Language:Chinese
-
Abstract:
Resistance to the cytotoxic actions of antineoplastic drugs remains a barrier to the establishment of curative chemotherapy regimens for cancer. Over-expression of P-glycoprotein (P-gp), encoded by the MDR1 gene is the major molecular mechanism enhancing efflux pump for various anticancer agents, hence caused MDR. Transcription factor, DNA methylation, histone acetylation/deacetylation, phosphorylation and glycosylation and MDR1 gene polymorphisms play pivotal role in regulation of P-glycoprotein, and may become new therapeutic targets. This paper summarized the advances of studies on expression and regulation of P-glycoprotein.
